Heartseed, Inc.TSE: 219A

Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscular

· Issued by Heartseed, Inc. via TDnet

Heartseed, Inc. (219A) Press Release

View Attachment

Company analysis